ESTRO 2023 - Abstract Book

S522

Sunday 14 May 2023

ESTRO 2023

Conclusion Brachytherapy plays an important role in UM. In fact, our results regarding LTC rate confirm this technique as first-choice treatment in medium-size tumors. In contrast to other studies, our results demonstrate a relationship between LTC and survival.

Further investigation should be done to know and understand other factors that might be involved in these results.

OC-0633 ESTRO abstract: The global Ruthenium Eye applicator survey - physicist responses L.S. Fog 1,2 , M. De Brabandere 3 , E. Placidi 4 , A. Slocker 5 , L. Tagliaferri 6 , Ȧ .C. Tedgren 7 , M. Andrássy 8 , C. Schulz 9 , E.C. Chimfwembe 10 , F. Siebert (chair of BRAPHYQS) 11 1 Alfred Health Radiation Oncology, Medical Physics, Melbourne, Australia; 2 Royal Victorian Eye and Ear Hospital, Ocular Oncology, Melbourne, Australia; 3 UZ Leuven, Medical Physics, Leuwen, Belgium; 4 Policlinico Universitario Agostino Gemelli IRCCS, Medical Physics, Rome, Italy; 5 Catalan Institute of Oncology, Medical Physics, Barcelona, Spain; 6 Policlinico Universitario Agostino Gemelli IRCCS, Radiation Oncology, Rome, Italy; 7 Linköping University, Karolinska Institute and Karolinska University hospital, Medical Physics, Linköping, Sweden; 8 Eckert and Ziegler, BEBIG, Berlin, Germany; 9 Eckert and Ziegler , Bebig, Berlin, Germany; 10 ESTRO, ., Bruxelles, Belgium; 11 UKSH, Campus Kiel, Clinic of Radiotherapy, Kiel, Germany Purpose or Objective Ruthenium plaque brachytherapy is an eye-preserving treatment for choroidal melanoma with good treatment outcomes [1]. It is a niche treatment, performed in only about 100 clinics worldwide [2].